ProQR Therapeutics N.V.

ProQR Therapeutics N.V. is a clinical-stage biotechnology company based in Leiden, Netherlands, with a presence in Cambridge, Massachusetts, USA. The company, founded in 2012 by CEO Daniel A. de Boer, is dedicated to discovering and developing RNA therapeutics for severe genetic rare and common diseases, particularly those with no current treatment options. Its core business revolves around its proprietary Axiomer RNA editing platform technology, which aims to correct disease-causing mutations directly at the messenger RNA level.

The company's pipeline focuses on advancing RNA editing therapies. Its lead clinical program, AX-0810, targets NTCP for cholestatic diseases, with biliary atresia selected as the initial Phase 2 indication. Other programs in development include AX-0811 for cholestatic diseases, AX-0422 for Hurler syndrome, AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH), and AX-2402 for Rett syndrome. ProQR also maintains a strategic collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders.

Recent notable developments include the company's April 2026 investor event, where it highlighted pipeline expansion, including new programs AX-0811 and AX-0422, and announced a partnership with Ginkgo Bioworks for AI-enabled discovery. ProQR expects target engagement data for AX-0810 in the first half of 2026 and has a cash runway extending into mid-2027. In February 2026, the company announced board changes, with co-founder Dinko Valerio and Alison Lawton stepping down. Daniel A. de Boer continues to lead as Founder and CEO, a role he has held since the company's inception. Analysts generally hold a "Moderate Buy" consensus rating for ProQR Therapeutics.

Latest updates

ProQR Adds Boehringer Ingelheim Exec to Board Amid Pipeline Advancement

Event summary

  • ProQR Therapeutics nominated Lykke Hinsch Gylvin, current Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, to its Board of Directors.
  • The nomination requires shareholder approval at ProQR's upcoming Annual General Meeting.
  • Dr. Hinsch Gylvin brings over 20 years of experience in pharmaceutical leadership, previously holding senior roles at Novartis, AstraZeneca, Roche, Novo Nordisk, and Lundbeck.
  • She holds an MD from the University of Copenhagen and an EMBA from SBS Swiss Business School.

The big picture

The appointment of a seasoned executive like Dr. Hinsch Gylvin signals ProQR’s intent to accelerate its clinical programs and potentially seek larger partnerships. Bringing in a CMO from a major player like Boehringer Ingelheim suggests a desire to bolster governance and expertise as ProQR navigates the complexities of RNA therapy development and commercialization. This move is consistent with a broader trend of biotech companies seeking experienced industry veterans to guide them through later-stage development and potential market entry.

What we're watching

Governance Dynamics
The impact of Dr. Hinsch Gylvin’s experience in oncology, immunology, and rare diseases on ProQR’s strategic direction warrants close observation, particularly given the company’s focus on Axiomer™ technology.
Clinical Execution
The speed at which Dr. Hinsch Gylvin can influence clinical trial design and regulatory strategy will be a key indicator of her value to ProQR’s pipeline advancement.
Partner Alignment
How ProQR leverages Dr. Hinsch Gylvin’s relationships at Boehringer Ingelheim and other former employers to expand collaborations and access resources will be critical for long-term success.
CID: 2710